Scheinberg P.,Oncology Center
International Journal of Hematology | Year: 2013
The decision to pursue hematopoietic stem cell transplantation or immunosuppression as first therapy in severe aplastic anemia is currently based on age and availability of a histocompatible donor. The ability to predict hematologic response, relapse and clonal evolution could improve treatment allocation. In the past 15 years, telomeres have been implicated in clinical diseases such as aplastic anemia, pulmonary fibrosis, cirrhosis and cancer development. The clinical relevance of varying telomere lengths (TL) and/or mutations in genes of the telomerase complex (TERC, TERT) is evolving in aplastic anemia. A large retrospective analysis suggests that baseline TL associate with late events of hematologic relapse and clonal evolution in aplastic anemia patients treated initially with anti-thymocyte globulin-based therapy. Further laboratory experiments propose possible mechanistic insight into genomic instability of bone marrow cells derived from patients with critically short telomeres and/or mutation in telomerase genes. The possibility of modulating telomere attrition rate with sex hormones could positively affect clonal evolution rates in humans. This review will summarize studies in marrow failure that explore the association between telomeres and aplastic anemia outcomes. © 2013 The Japanese Society of Hematology.
Orphanos G.,Ygia Polyclinic |
Kountourakis P.,Oncology Center
Hematology/ Oncology and Stem Cell Therapy | Year: 2013
The advent of targeted therapies has revolutionized the treatment of certain types of cancer. Identification of molecular targets on cancer cells has led to the design of novel drugs, which either used as single agents or in combination with chemotherapy, has prolonged survival in metastatic disease, or contributed to curative treatment in the adjuvant setting. A literature review was conducted to identify and present current knowledge on the molecular function of the HER2 receptor, its role in the pathogenesis of breast cancer and anti-HER2 targeted drugs in use or under development. Many molecular targets have been identified in breast cancer, with the HER family of receptors being the ones most extensively studied. Trastuzumab and lapatinib target the HER2 receptor and are approved drugs for the treatment of metastatic breast cancer. Several other targeted agents, including T-DM1, pertuzumab, neratinib, afatinib and ertumaxomab, are currently being tested in vivo as well as in clinical studies. The use of targeted therapies in metastatic breast cancer has improved prognosis, increased survival and dramatically changed the way we treat breast cancer patients today.
Fashoyin-Aje L.A.,Oncology Center
Journal of Supportive Oncology | Year: 2012
The Commission on Cancer of the American College of Surgeons publishes accreditation standards that hospitals and cancer treatment centers implement to ensure quality care to cancer patients. These standards address the full spectrum of cancer care, from cancer prevention to survivorship and end-of-life care. The most recent revisions of these standards included new standards in "patient-centered areas," including the provision of palliative care services, treatment and survivorship plans, psychological distress screening, and patient navigation programs. Unified by their emphasis on the early identification of patients at risk of receiving suboptimal care and the importance of ensuring that issues arising during and after completion of cancer treatment are addressed, they are a welcome expansion of the standards guiding cancer care. As with all standards, however, the next steps will be to further define how they will be implemented and to determine how success will be assessed. This will require ongoing critical evaluation of the standards and their implementation, including the need for member institutions to define successful implementation methods and measurable outcomes and identification of areas most in need of further research. © 2012 Elsevier Inc.
Schaffer M.,Institute of Oncology |
Schaffer P.M.,Oncology Center |
Zidan J.,Institute of Oncology |
Sela G.B.,University of Sfax
Current Opinion in Clinical Nutrition and Metabolic Care | Year: 2011
Purpose of Review: Several nutritional compounds are the focus of public attention because of their potential beneficial health effects. Turmeric is a spice that comes from the root Curcuma longa. Extensive research over the past half century and especially in recent years has revealed important functions of curcumin and a timely review of clinical state-of-the-art using curcumin. Recent Findings: In-vitro and in-vivo research has shown various activities, such as anti-inflammatory, antiviral, antifungal, cytokines release, antioxidant, immunomodulatory, enhancing of the apoptotic process, and antiangiogenic properties. Curcumin also have been shown to be a mediator of chemo-resistance and radio-resistance. Summary: Various in-vitro and in-vivo and scarce number of clinical studies on curcumin were identified. The various effects and properties of curcumin are summarized in this review, including preclinical and especially clinical studies. This review concentrates on recent knowledge and research with curcumin clinical applications, and clinical studies, focusing on studies published between 2008 and 2011 demonstrating the gap between preclinical and clinical research. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Marta G.N.,Oncology Center
Expert review of anticancer therapy | Year: 2011
Meningiomas are tumors that arise from arachnoid cap cells, which surround and adhere to the dura mater. Currently, meningiomas comprise 13-30% of primary intracranial tumors and are only less frequent than gliomas. In this article an overview of meningiomas is presented, with brief mention to their epidemiology, clinical presentation, histopathological and imaging features. The main therapies for meningiomas are also presented, focusing on radiation. In this article the authors conclude that the epidemiological, imaging and histopathological features and the clinical presentation of meningiomas are well-defined. Despite the need for randomized trials and larger studies with long median follow-up, radiotherapy can be used as an alternative treatment to surgery either as a first-line treatment or at its recurrence. Various conventional radiotherapy techniques can be employed for residual tumor or at recurrence.